Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company. The company is focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has discovered and is developing small molecule Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein (XPO1). The company's SINE compounds were the first oral XPO1 inhibitors in clinical development. The company's focus is on seeking the commercialization of its primary drug candidate, selinexor (KPT-330), as an oral agent in cancer indications with clinical need, initially for hematologic malignancies.
  • TickerKPTI
  • ISINUS48576U1060
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

KARYOPHARM THERP.INCO. sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of KARYOPHARM THERP.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date October 8, 2019, the closing price was USD 9.56 and its target price was estimated at USD 5.24.

Wedbush Research

Wedbush Morning Call - Oct 08 2019

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Oct 08 2019

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Initiating at OUTPERFORM; Drink Deep or Taste not this Pierian Spring... Works

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

ESMO 2019 Roundup for Covered Companies

A director sold after exercising options/sold 27,042 shares at 9.919USD and

A director at Karyopharm Therapeutics Inc sold after exercising options/sold 27,042 shares at 9.919USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restri...

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

KARYOPHARM THERP.INCO. sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of KARYOPHARM THERP.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date October 8, 2019, the closing price was USD 9.56 and its target price was estimated at USD 5.24.

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch